Latest News about atopic dermatitis
Recent news which mentions atopic dermatitis
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
May 16, 2024
From Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
From Benzinga
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older
January 18, 2022
Tickers
ABBV
From Benzinga
EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa
November 30, 2021
Tickers
HOTH
From Benzinga
AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
September 30, 2021
Tickers
ABBV
From Benzinga
Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis
September 30, 2021
Tickers
PFE
From Benzinga
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
September 27, 2021
Tickers
ASLN
From Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
September 22, 2021
Tickers
INCY
From Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
From Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
August 30, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.